Table 2 |
||||||||
|
Trials testing passionflower |
||||||||
|
Reference |
Study Design |
Sample Population |
Intervention |
Control |
Length of Treatment |
Outcomes |
Direction of Evidence |
Reported Adverse Events |
|
|
||||||||
|
Bourin (1997) [34] |
Randomized; Double-blind; Parallel Group |
182 outpatients with adjustment disorder with anxious mood |
Euphytose1; 2 tablets, 3 times a day |
Placebo tablets |
28 days |
Significant reduction in HAMA scores (from D7 to D28) in favour of Euphytose treatment |
+ |
No serious AEs. Dry mouth Headache Constipation Drowsiness |
|
|
||||||||
|
Akhondzadeh (2001) [32] |
Randomized; Double-blind; Parallel group |
36 outpatients with DSM-IV for GAD for at least 6 months |
45 drops/day of Passiflora extract plus placebo tablet |
Oxazepam 30 mg/day plus placebo drops |
4 weeks |
Decrease in HAMA for both treatments2; overall no significant difference in efficacy between treatments |
+ |
Higher impairment of job performance in oxazepam group; overall no significant difference in total side effects3 |
|
|
||||||||
|
Movafegh (2008) [33] |
Randomized; Double-blind; Parallel Group |
60 patients undergoing inguinal herniorrhaphy |
Oral Passiflora incarnata (500 mg, Passipy™ IranDarouk) |
Placebo |
Given as pre-medication 90 minutes before surgery |
NRS anxiety scores were significantly lower in the passiflora group |
+ |
Not reported |
|
|
||||||||
|
AEs: Adverse events; HAMA: Hamilton Anxiety Scale; DMS-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety disorder; NRS: numerical rating scale. 1. Combination of Crataegus oxyacantha (10 mg), Ballota foetida (10 mg), Passiflora incarnata (40 mg), Valeriana officinalis (50 mg), Cola nitida (15 mg) and Paullinia cupana (15 mg). 2. D4 oxazepam; D7 passiflora. 3. Passiflora, mild/moderate: Dizziness, Drowsiness, Confusion, Ataxia, Allergic reaction, Impairment of job performance. |
||||||||
|
Lakhan and Vieira Nutrition Journal 2010 9:42 doi:10.1186/1475-2891-9-42 |
||||||||